FIP1L1-PDGFRA Analysis in Eosinophilia Diagnosis
Author Information
Author(s): Loules Gedeon, Kalala Fani, Giannakoulas Nikolaos, Papadakis Emmanouil, Matsouka Panagiota, Speletas Matthaios
Primary Institution: University of Thessaly Medical School, University Hospital of Larissa, Greece
Hypothesis
What is the prevalence and the associated clinicopathologic and genetic features of FIP1L1-PDGFRA rearrangement in patients with eosinophilia?
Conclusion
Early diagnosis of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and treatment with imatinib can lead to excellent clinical outcomes.
Supporting Evidence
- Two patients with FIP1L1-PDGFRA rearrangement responded well to imatinib treatment.
- The study found a 13.3% prevalence of FIP1L1-PDGFRA rearrangement in the cohort.
- Patients with idiopathic hypereosinophilic syndrome also showed positive responses to imatinib.
Takeaway
This study looked at patients with high eosinophil counts to see if a specific gene change was present, which can help doctors give better treatment.
Methodology
The study used RT-PCR to detect FIP1L1-PDGFRA rearrangement and confirmed results with direct sequencing.
Limitations
The sample size was small, which may affect the generalizability of the findings.
Participant Demographics
7 males and 8 females, mean age 45.2 years (range: 22–72 years).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website